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Title 
Dose-volume metrics associated with radiation pneumonitis after 
stereotactic body radiation therapy for lung cancer 
 
Abstract 
Purpose: To identify dose-volume factors associated with radiation pneumonitis (RP) after 
stereotactic body radiotherapy (SBRT) for lung cancer. 
Methods and Materials: This study analyzed 74 patients who underwent SBRT for primary 
lung cancer. The prescribed dose for SBRT was uniformly 48 Gy in four fractions at the 
isocenter. RP was graded according to the Common Terminology Criteria for Adverse Events 
(CTCAE) ver.3. Symptomatic RP was defined as Grade 2 or worse. Optimal cut-offs 
dividing the patient population into two subgroups based on the incidence of symptomatic 
RP were sought using the following dose-volume metrics: PTV volume (mL), mean lung 
dose (Gy), and V5, V10, V15, V20, V25, V30, V35, and V40 (%) of both lungs excluding the 
PTV. 
Results: With a median follow-up duration of 31.4 months, symptomatic RP was observed in 
15 patients (20.3%), including one patient with Grade 3. Optimal cut-offs for pulmonary 
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dose-volume metrics were V25 and V20. These two factors were highly correlated with each 
other, and V25 was more significant. Symptomatic RP was observed in 14.8% of the patients 
with V25 <4.2%, and the rate was 46.2% in the remainder (P = 0.019). PTV volume was 
another significant factor. The symptomatic RP rate was significantly lower in the group with 
PTV <37.7 mL compared with the larger PTV group (11.1% vs. 34.5%, P = 0.020). The 
patients into three subgroups― (1) PTV <37.7 mL; (2) PTV ≥37.7 mL and V25 <4.2%; and 
(3) PTV ≥37.7 mL and V25 ≥4.2%―and the incidence of RP Grade 2 or worse was 11.1, 
23.5, and 50.0%, respectively (P = 0.013). 
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Running title 
Dose-volume metrics and RP after SBRT for lung cancer 
Summary: 
 
To identify dose-volume factors associated with radiation pneumonitis (RP) after stereotactic body 
radiation therapy (SBRT) for lung cancer, this study analyzed 74 patients who underwent SBRT for 
primary lung cancer. RP Grade 2 or worse was observed in 15 patients (20.3%). Lung V25 and PTV 
volume were significant factors. SBRT with PTV ≥37.7 mL and lung V25 ≥4.2% indicated a 50% 
risk of RP Grade 2 or worse. 
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Introduction 
Stereotactic body radiation therapy (SBRT) consists of two key features. One is its 
high accuracy, which allows delivery of a high dose to a very limited volume, while 
limiting the dose to normal tissues. The other key feature is hypofractionation. With 
conventional radiotherapy, schedules of 30–40 fractions are commonly used with a total 
dose of 60–74 Gy for lung cancer. SBRT is usually performed in a single fraction or 2–5 
fractions with a much higher fractional dose (6–20 Gy). These key features of SBRT lead to 
high control rates of local tumors
1,2
. SBRT should improve the prognosis for inoperable or 
elderly patients with early stage non-small-cell lung cancer (NSCLC).
3
 
The safety of SBRT is being confirmed in multi-institutional phase 2 trials for 
peripheral lung cancer in inoperable
1,4
 and operable patients
2
. In the Radiation Therapy 
Oncology Group (RTOG) trial 0236,
1
 protocol-specified treatment-related Grade 3 and 4 
adverse events occurred in 12.7 and 3.6%, respectively. No Grade 5 adverse events were 
reported. In the Nordic phase 2 study of SBRT,
4
 Grade 3 toxicity was seen in 21%. No 
Grade 4 or 5 toxicity was reported. Nagata et al. reported Grade 3 toxicity in 6.2% of 
operable patients in the Japan Clinical Oncology Group (JCOG) 0403.
2
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Radiation pneumonitis (RP) is one of the most common toxicities after SBRT, as 
well as after conventional radiotherapy to the lung. The reported rates of symptomatic RP 
after SBRT range from 9 to 28%.
5–11
 Although most of the RP was Grade 2 and manageable, 
a few cases were severe, and there is a potential risk of mortality
5
. It is very important to 
develop a method to predict the risk of RP after SBRT for the lung. 
The dose-volume metrics from a treatment plan might be a predictor for RP. In 
conventional radiotherapy for the lung, many dose-volume data are available, and dose 
constraints have been proposed to reduce the risk of pneumonitis. The Quantitative 
Analysis of Normal Tissue Effects in the Clinic (QUANTEC) recommended a lung V20 
≤30–35% and mean lung dose (MLD) ≤20–23 Gy to limit the risk of RP to ≤20%  in 
definitive radiotherapy for NSCLC with conventional fractionation.
12
 However, there is no 
established criterion regarding dose-volume factors in hypofractionated SBRT. Therefore, 
we searched for dose-volume factors associated with RP after SBRT for lung cancer. 
 
Materials and Methods 
This study analyzed consecutive 74 patients who underwent SBRT for pathology 
proven NSCLC from September 2003 to March 2008. All patients were diagnosed as stage 
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I lung cancer based on CT. The eligibility criteria for SBRT for stage I lung cancer were as 
follows: (1) surgery was contraindicated or refused; (2) maximal tumor diameter was 40 
mm or less; (3) the tumor was not adjacent to mediastinal organs (spinal cord, esophagus, 
heart, and main bronchus); (4) the patient could remain stable for longer than 30 min with 
ECOG performance status (PS) of 0–2; (5) the patient had no active interstitial 
pneumonitis; and (6) written informed consent was obtained. The patient characteristics are 
shown in Table 1. For these patients, the prescribed dose of SBRT was uniformly 48 Gy in 
four fractions at the isocenter. A median in overall treatment time was 5 days (range, 4–12 
days). Chemotherapy was not administered unless disease progression was confirmed. 
 
SBRT procedure 
Details of our SBRT procedure have been described in our previous reports.
13,14
 The 
patient’s body was immobilized with a stereotactic body frame (Elekta AB, Stockholm, 
Sweden). Irradiation was performed with 6-MV x-ray beams from a linear accelerator 
(Clinac 2300 C/D; Varian Medical Systems, Palo Alto, CA) with multiple non-coplanar 
static ports (5–8 ports). The beams were shaped into a planning target volume (PTV) plus 
5-mm margins using multi-leaf collimators. 
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The SBRT was planned with the Eclipse (Varian Medical Systems) treatment 
planning system. An internal target volume (ITV) was determined using computed 
tomography (CT) with a slow-scan technique, considering tumor motion assessed by x-ray 
fluoroscopy. The PTV was defined as the ITV with a 5-mm margin for setup uncertainty. To 
delineate lung volumes, the segmentation wizard in Eclipse was applied to the slow-scan 
CT images with a threshold value of –300 Hounsfield units (HU). Then, the lung volumes 
were trimmed manually to remove overlapping regions involving the PTV and bronchi. 
 
RP grading 
The patients were followed-up 1, 2, 4, 6, 9, and 12 months after the SBRT, then 
every 3 months for years 2 to 5, and then every 6 months thereafter. CT was performed 
every 2–4 months in the first year, every 6 months between years 1 and 5 after the 
treatment, and annually thereafter. 
Radiation pneumonitis was assessed according to the Common Terminology 
Criteria for Adverse Events (CTCAE) ver.3 for pneumonitis, which consists of the 
following grades: Grade 1, asymptomatic with radiographic findings only; Grade 2, 
symptomatic and not interfering with the activities of daily living (ADL); Grade 3, 
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symptomatic, interfering with the ADL and O2 indicated; and Grade 4, life-threatening, 
ventilatory support indicated. We defined symptomatic RP as Grade 2 or worse. 
 
Evaluated data and statistical analysis 
The dose-volume metrics were re-calculated using the Analytical Anisotropic 
Algorithm (AAA) with the same monitor units as used in the clinical setting. The grid size 
for the calculation was 2.5 × 2.5 × 2.5 mm
3
. 
The following dose-volume metrics were evaluated in this study: PTV volume (mL), 
MLD (Gy), and V5, V10, V15, V20, V25, V30, V35, and V40, where Vd is the relative 
volume of normal lung (%) that received more than a threshold dose of d Gy. We defined 
normal lung as both lungs excluding the PTV. 
The optimal cut-offs dividing the patient population into two subgroups based on 
the incidence of symptomatic RP were searched using the recursive partitioning method. 
After dividing the groups, the occurrence rates for symptomatic RP were compared using 
Fisher’s exact test. R version 2.13.1 with the rpart package (R Foundation for Statistical 
Computing, Vienna, Austria) was used for statistical analyses. Statistical significance was 
defined as P < 0.05. 
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Results 
With a median follow-up duration of 31.4 (range 4.2–65.0) months, symptomatic 
RP was observed in 15 patients (20.3%), consisting of 14 patients with Grade 2 and one 
with Grade 3. RP was diagnosed based on symptoms with radiologic findings. A median 
time to symptomatic RP was 4.5 months (range, 1.1–16.1 months). 
Table 2 summarizes the dose-volume metrics of the PTV and normal lung. The PTV 
ranged from 9.9 to 86.6 mL (median 32.5 mL). The median MLD was 3.2 (range 1.6–7.6) 
Gy. The median lung V20 and V25 were 4.4% and 2.9%, respectively. The lung metrics 
(MLD and V5–40) were highly correlated with each other, with correlation coefficients (R) 
of 0.61–0.99. In contrast, the correlations between the PTV volume and lung metrics were 
weak (R = 0.37–0.59). The PTV volume, MLD, V20 and V25 were respectively 42.1 mL, 
3.7 Gy, 5.4% and 3.8% in mean for Grade 2 RP patients. Those values were respectively 
38.1 mL, 4.0 Gy, 5.0% and 3.3% for a Grade 3 patient. 
The optimal cut-offs for the dose-volume metrics are shown in Table 3. Lung V25 
and V20 were significant factors, and V25 was more significant. The rate of symptomatic RP 
was 14.8% in the patients with V25 <4.2%, whereas the rate was 46.2% in the remainder 
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(P = 0.019). The PTV volume was another significant factor. The symptomatic RP rate was 
significantly lower in the group with PTV <37.7 mL compared with the larger PTV group 
(11.1% vs. 34.5%, P = 0.020). On classifying the patient population into three subgroups― 
(1) PTV <37.7 mL (n = 45); (2) PTV ≥37.7 mL and V25 <4.2% (n = 17); and (3) PTV ≥37.7 
mL and V25 ≥4.2% (n = 12)― the incidence of symptomatic RP was 11.1, 23.5, and 50.0%, 
respectively (P = 0.013). 
 
Discussion 
We investigated the dosimetric factors associated with symptomatic RP (≥Grade 2) 
after SBRT, and found that PTV and lung V25 were significant factors. The optimal 
cut-offs for these factors (PTV <37.7 mL and V25 <4.2%) were much lower than 
prespecified constraints which other SBRT trials used to mainly limit the risk of Grade 3 
toxicities (e.g. MLD <18Gy, lung V40 <100mL, V15 <25% and V20 <20% for the JCOG 
0403 trial; and lung V20 <10% for the RTOG 0236). As only one patient suffered from 
Grade 3 RP in our cohort, it was difficult to build a model for predicting severe RP (e.g., 
Grade 3 or worse). Severe RP is uncommon after SBRT for the lung. Grade 3 RP was 
observed in 3.6% of the patients in the RTOG 0236
1
 and in 3.1% of the operable patients in 
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JCOG 0403.
2
 Baumann et al. reported that no one developed Grade 3 pneumonitis in their 
phase 2 trial of SBRT.
4
 
Table 4 summarizes reports that focused on the dose-volume metrics associated with 
RP Grade 2 or worse after SBRT. The RP rates varied from 9.4–28.0%, and the suggested 
dose-volume factors for RP differed among the reports. This variation might be caused by 
differences in the PTV volume, dose-fractionation schedule, and RP scoring system. 
The scoring criteria for RP differ among toxicity-grading systems. Steroid use for 
pneumonitis is scored as Grade 3 in the RTOG system, whereas the Common Toxicity 
Criteria (CTC) ver.2 scores symptomatic patients requiring steroids as Grade 2. CTCAE 
ver.3 removed steroid use from the pneumonitis scoring system. From CTCAE ver.3 to 
ver.4, the pneumonitis score was modified slightly. Grade 2 pneumonitis in CTCAE ver.4 
was defined as “symptomatic, medical intervention indicated or limiting instrumental 
ADL.” The number of patients considered to have RP depends on which system is used to 
evaluate RP. Tucker et al. retrospectively evaluated 442 patients who received definitive 
radiotherapy for NSCLC using the three RP grading systems: RP Grade 2 or worse was 
observed in 129 (29%), 109 (25%), and 195 (44%) patients according to RTOG, CTC ver.2 
and CTCAE ver.3, respectively.
15
 The rate of Grade 2–3 RP according to CTCAE ver.3 
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seemed to be slightly higher (20.3%) in our study compared with other studies that 
evaluated it using CTC ver.2 or the RTOG system. Nevertheless, we administered steroids 
to six patients (8.1%) only. Scoring systems should be considered when interpreting the 
results regarding RP. 
This study indicated that a large PTV is a significant risk factor for symptomatic RP 
after SBRT. Ong et al. treated large tumors in 18 patients with a PTV >80 mL (median 137 
mL) with SBRT using volumetric modulated arc therapy.
9
 They reported five patients 
(27.8%) with RP Grade 2–3. We speculate that the large PTV volume was one of the 
reasons for their relatively high risk of pneumonitis. From our results, minimizing the PTV 
is one way to limit the RP risk. When a lung tumor has large respiratory motion, respiration 
management will contribute to the prevention of RP by reducing the PTV. 
To correct for differences in dose-fractionation, three reports
6–8
 in Table 4 used 
normalized total doses (NTD), which were equivalent doses in 2-Gy fractions in terms of 
pulmonary toxicity. Borst et al. evaluated the relationship between the MLD and incidence 
of RP after SBRT.
7
 They calculated the MLD in the NTD form using the linear-quadratic 
model with an α/β ratio of 3 Gy. A significant dose–response relationship was found 
between RP and MLD. We used a uniform dose fractionation of 48 Gy in four fractions for 
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all of our patients, and we evaluated dosimetric factors in the form of a nominal dose. 
Although we cannot apply normalization to our data exactly, the median MLD was roughly 
estimated to be 3.7 Gy in NTD. The usefulness of NTD evaluation for pulmonary toxicity 
after SBRT should be validated in future studies. 
Heterogeneity correction and the definition of lung volume may influence the 
dose-volume factors of the lung. De Jaeger et al. evaluated differences between the 
equivalent-pathlength (EPL) and convolution–superposition (CS) algorithms in MLD and 
V20 for 68 patients treated with conformal radiotherapy for NSCLC.
16
 MLD and V20 
differed between the two algorithms by 16.9% and 12.0% on average, respectively. The 
TD50 for RP Grade 2 or worse in MLD was estimated to be 34.1 Gy with the EPL algorithm, 
whereas the value was 29.2 Gy with the CS algorithm. Because most related reports have 
used convolution–superposition algorithms, we applied the AAA, which is a 
convolution–superposition algorithm, to recalculate the dose-volume data so as to limit the 
influences of heterogeneity correction. 
 Our definition of lung volume was both lungs segmented with a threshold value of 
–300 HU on slow-scan CT from which PTV was excluded. Lung volume can vary 
depending on which lung is evaluated (ipsilateral, contralateral, or bilateral), exclusion of 
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tumor volume (GTV or PTV), type of planning CT (slow-scan CT, 4D CT, or breath-hold 
CT), and the threshold HU for segmentation. When the PTV is subtracted from the lung 
volume, a high-dose volume within the PTV margin is not evaluated as dose-volume 
factors for the lung. These conditions were not always stated in the previous papers, and 
future articles should include this information. 
Factors other than the dose-volume metrics also affect the occurrence of 
pneumonitis after SBRT. The serum level of Krebs von den Lungen-6 (KL-6) is a predictor 
of RP. Hara et al. evaluated 16 patients who received single-fraction SBRT with 20–35 
Gy.
17
 The relative increase in the serum KL-6 between before and at 2 months after SBRT 
was significantly correlated with the occurrence of Grade 3 RP by the RTOG criteria. Iwata 
et al. reported that the pretreatment serum KL-6 levels, gender, and PTV volume were 
correlated with symptomatic RP in a univariate analysis, and the pretreatment KL-6 levels 
remained significant in a multivariate analysis.
18
 They concluded that patients with a 
pretreatment KL-6 level ≥300 U/mL should be followed carefully for the occurrence of RP. 
CT or x-ray imaging before and after SBRT should help to predict severe RP. Yamashita et 
al. recommended prescreening of interstitial pneumonitis on CT, in addition to checking the 
serum KL-6 and surfactant protein-D (SP-D) levels to limit the risks of severe RP.
19
 They 
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reported that after introducing the prescreening, the occurrence rate of RP Grade 4–5 
decreased from 18.8% to 3.5%. Takeda et al. reported that the early appearance of RP on 
chest x-ray after SBRT was correlated with the severity of RP.
20
 The radiographic 
appearance of RP during the initial 2 months indicated a 40% risk for Grade 3 RP, whereas 
the risk was only 1.2% when the radiologic change appeared 3 months after SBRT. 
Considering biomarkers (KL-6 and SP-D) and radiologic imaging as well as dose-volume 
factors helps us to limit the risks for severe pneumonitis after SBRT. 
Our study has some limitations. First, this study was based on a retrospective 
review; thus, it was prone to selection bias. Second, the number of RP events was limited in 
the present study. Prospective data are awaited to investigate a correlation between 
pulmonary toxicities and dosimetric factors. The other limitation was that clinical factors 
other than dose-volume metrics were not taken into consideration, as described above. 
In conclusion, this study found that the lung V25 and PTV volumes were significant 
factors associated with RP after SBRT. SBRT with PTV ≥37.7 mL and lung V25 ≥4.2% 
indicated a 50% risk of RP Grade 2 or worse. 
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Table 1. Patient characteristics 
* Others included 3 large cell carcinomas and 5 non-small cell carcinomas not other specified. 








Median (range) 77 (63–88) 



















Squamous cell carcinoma 30 
 
Others* 8 









   Median (range) 
PTV Volume (mL) 32.5 (9.9–86.6) 
Lung Mean dose (Gy) 3.2 (1.6–7.6) 
 V40 (%) 0.7 (0–2.9) 
 V35 (%) 1.4 (0.2–4.8) 
 V30 (%) 2.0 (0.5–6.6) 
 V25 (%) 2.9 (0.9–9.5) 
 V20 (%) 4.4 (1.7–13.1) 
 V15 (%) 6.7 (2.6–18.2) 
 V10 (%) 10.3 (4.4–25.1) 
 V5 (%) 16.7 (7.1–37.3) 
 








PTV (mL) 37.7 11.1% 34.5% 0.020* 
MLD (Gy) 4.7 17.2% 40.0% 0.110 
V40 (%) 1.6 17.6% 50.0% 0.093 
V35 (%) 1.9 15.3% 40.0% 0.066 
V30 (%) 2.8 15.3% 40.0% 0.066 
V25 (%) 4.2 14.8% 46.2% 0.019* 
V20 (%) 5.8 15.0% 42.9% 0.030*  
V15 (%) 4.9 5.3% 25.5% 0.096 
V10 (%) 10.1 11.4% 28.2% 0.089 
V5 (%) 26.8 17.9% 42.9% 0.143 
 
Table 3. Optimal cut-off values and crude rates of symptomatic RP 
Abbreviations: RP = radiation pneumonitis, MLD = mean lung dose 
Asterisks (*) mean statistical significance.









PTV volume (mL) 
[median (range)]  







Yamashita5 2007 25 48 Gy/ 4–6 fr CC 43.9 (7.5–239.4) 28.0% CTCAE v3 CI 
Ricardi6 2009 60 
45 Gy/ 3 fr 
 or 26 Gy/ 1 fr 
CC NA 14.3% RTOG 
MLD† (ips. 
lung-CTV) 
Borst7 2009 128 35–60 Gy/ 4–8 fr CS 
9.6 (0.2–106.9) 
in GTV 






26 Gy/ 1 fr 
 or 37.5 Gy/ 3 fr 




Ong9 2010 18 
55 Gy/ 5 fr 
 or 60 Gy/ 8 fr 
AAA 137 (87–286) 27.8% CTCAE v4 
V5 (con. 
lung) 








Present study   74 48 Gy/ 4 fr AAA 32.5 (9.9–86.6) 20.3% CTCAE v3 
PTV volume 
and V25 (bil. 
lung-PTV) 
 Table 4. Summary of reports on dose-volume factors associated with radiation pneumonitis Grade 2 or worse after 
stereotactic body radiation therapy 
* The authors reported that tissue heterogeneity was corrected in some of the patients, but information on the heterogeneity correction 
algorithm was not available. 
† The MLD was evaluated using the normalized total dose, which is the equivalent dose in 2-Gy fractions. 
Abbreviations: RP = radiation pneumonitis, NA = not available, CC = collapsed cone convolution superposition, CS = convolution 
superposition, AAA = analytical anisotropic algorithm, CTC = common toxicity criteria, CTCAE = common terminology criteria for adverse 
events, RTOG = Radiation Therapy Oncology Group, SWOG = Southwest Oncology Group, CI = conformity index, MLD = mean lung dose, 
ips. = ipsilateral, con. = contralateral, bil. = bilateral 
